3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Status
Completed
16
Recruiting
5
Terminated
4
Unknown
3
Not yet recruiting
3
Withdrawn
1
Active not recruiting
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Gynecologic
1
CNS
1
Breast
1
Conditions
Colorectal Neoplasms
57
Carcinoma, Non-Small-Cell Lung
29
Breast Neoplasms
18
Rectal Neoplasms
14
Ovarian Neoplasms
13
Neoplasm Metastasis
10
Carcinoma, Hepatocellular
10
Glioblastoma
9
Colonic Neoplasms
9
Carcinoma, Renal Cell
8
Fallopian Tube Neoplasms
7
Uterine Cervical Neoplasms
6
Brain Neoplasms
6
Neoplasms
5
Nasopharyngeal Carcinoma
5
Lung Neoplasms
5
Triple Negative Breast Neoplasms
4
Inflammatory Breast Neoplasms
4
Colorectal Cancer Metastatic
4
Carcinoma, Ovarian Epithelial
4
Stomach Neoplasms
3
Recurrence
3
Pleural Effusion, Malignant
3
Meningeal Carcinomatosis
3
Melanoma
3
Liver Neoplasms
3
Kidney Neoplasms
3
Glioma
3
Non-squamous Non-small Cell Lung Cancer
2
Liver Metastasis Colon Cancer
2
Interventions
Cyclophosphamide
17
fludarabine
13
Dexamethasone
12
Cisplatin
11
Rituximab
10
Gemcitabine
9
Paclitaxel
7
Lenalidomide
7
Decitabine
7
Cytarabine
7
Bendamustine Hydrochloride
7
fludarabine phosphate
6
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
6
Etoposide
6
Carboplatin
6
Bortezomib
6
Radiotherapy
5
Injections
5
Azacitidine
5
camrelizumab
4
apatinib
4
Valproic Acid
4
Thalidomide
4
Procarbazine
4
Oxaliplatin
4
Drug Therapy
4
Antilymphocyte Serum
4
tislelizumab
3
pomalidomide
3
liposomal doxorubicin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Unknown
×
Recurrence
×
Bevacizumab
×
Clear all
NCT04739670
2024-03-01
BELLA
Peter MacCallum Cancer Centre, Australia
Phase 2
Unknown
31 enrolled
NCT02761070
2023-03-08
RE-GEND
Kyorin University
Phase 3
Unknown
146 enrolled
NCT04015739
2022-08-17
BOLD
ARCAGY/ GINECO GROUP
Phase 2
Unknown
74 enrolled